Immunotherapy advances

Keyphrases

Publications

volume 4, number 1, 2024

Ashna Patel, Mikhail A Kutuzov, Michael L Dustin, P Anton van der Merwe, Omer Dushek
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells. Immunotherapy advances 4 (1) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Ashna Patel, Mikhail A Kutuzov, Michael L Dustin, P Anton van der Merwe, Omer Dushek
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells. Immunotherapy advances 4 (1) (2024)
Farhana Khamarudin, Mudiana Muhamad, Mohamad Johari Ibahim, Wan Nor I'zzah Wan Mohamad Zain, Mardiana Abdul Aziz, Nurul Raudzah Adib Ridzuan, Sharaniza Ab-Rahim
Establishment of humanised xenograft models as in vivo study for lung metastasis of osteosarcoma. Immunotherapy advances 4 (1) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Katty Zeven, Yoline Lauwers, Lynn De Mey, Jens M Debacker, Tessa De Pauw, Timo W M De Groof, Nick Devoogdt
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy. Immunotherapy advances 4 (1) (2024)
Farhana Khamarudin, Mudiana Muhamad, Mohamad Johari Ibahim, Wan Nor I'zzah Wan Mohamad Zain, Mardiana Abdul Aziz, Nurul Raudzah Adib Ridzuan, Sharaniza Ab-Rahim
Establishment of humanised xenograft models as in vivo study for lung metastasis of osteosarcoma. Immunotherapy advances 4 (1) (2024)
Peng Chen, Yiwei Chu, Ronghua Liu
Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects. Immunotherapy advances 4 (1) (2024)
Peng Chen, Yiwei Chu, Ronghua Liu
Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects. Immunotherapy advances 4 (1) (2024)

volume 4, number 1, 2023

Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Kathleen Richter, Halimu N Haliduola, Jana Schockaert, Aurélie Mazy, Nataliya Reznichenko, Eric Guenzi, Fausto Berti
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira ® or undergoing repeated switches between Humira ® and AVT02. Immunotherapy advances 4 (1) (2023)
Shania Makker, Charlotte Galley, Clare L Bennett
Cancer vaccines: from an immunology perspective. Immunotherapy advances 4 (1) (2023)
J Guillaume, A Perzolli, Marianne Boes
Strategies to overcome low MHC-I expression in paediatric and adult tumours. Immunotherapy advances 4 (1) (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Shania Makker, Charlotte Galley, Clare L Bennett
Cancer vaccines: from an immunology perspective. Immunotherapy advances 4 (1) (2023)
J Guillaume, A Perzolli, Marianne Boes
Strategies to overcome low MHC-I expression in paediatric and adult tumours. Immunotherapy advances 4 (1) (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Kathleen Richter, Halimu N Haliduola, Jana Schockaert, Aurélie Mazy, Nataliya Reznichenko, Eric Guenzi, Fausto Berti
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira ® or undergoing repeated switches between Humira ® and AVT02. Immunotherapy advances 4 (1) (2023)
Shania Makker, Charlotte Galley, Clare L Bennett
Cancer vaccines: from an immunology perspective. Immunotherapy advances 4 (1) (2023)

volume 3, number 1, 2023

Megan Sykes
Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity. Immunotherapy advances 3 (1) (2023)
Michael J Walsh, Lestat R Ali, Patrick Lenehan, Courtney T Kureshi, Rakeeb Kureshi, Michael Dougan, David M Knipe, Stephanie K Dougan
Blockade of innate inflammatory cytokines TNF α , IL-1 β , or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunotherapy advances 3 (1) (2023)
Akshay Jatin Patel, Gary W Middleton
TIGIT-based immunotherapeutics in lung cancer. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Andrew Abaasa, Moses Egesa, Emmanuella Driciru, Jan Pieter R Koopman, Ronald Kiyemba, Richard E Sanya, Jacent Nassuuna, Agnes Ssali, Geofrey Kimbugwe, Anne Wajja, Govert J van Dam, Paul L A M Corstjens, Stephen Cose, Janet Seeley, Dorcas Kamuya, Emily L Webb, Maria Yazdanbakhsh, Pontiano Kaleebu, Afzal A Siddiqui, Narcis Kabatereine, Edridah Tukahebwa, Meta Roestenberg, Alison M Elliott
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Shimon Sakaguchi, Ryoji Kawakami, Norihisa Mikami
Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. Immunotherapy advances 3 (1) (2023)
Walter Bodmer
A historical perspective on HLA. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Meiyin Lin, Sebastian Chakrit Bhakdi, Damien Tan, Joycelyn Jie Xin Lee, David Wai Meng Tai, Andrea Pavesi, Lu-En Wai, Tina Wang, Antonio Bertoletti, Anthony Tanoto Tan
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. Immunotherapy advances 3 (1) (2023)
Shuya Kaneko, Fumiaki Sakura, Kay Tanita, Asami Shimbo, Ryusuke Nambu, Masashi Yoshida, Shuichiro Umetsu, Ayano Inui, Chizuru Okada, Miyuki Tsumura, Mamiko Yamada, Hisato Suzuki, Kenjiro Kosaki, Osamu Ohara, Masaki Shimizu, Tomohiro Morio, Satoshi Okada, Hirokazu Kanegane
Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function. Immunotherapy advances 3 (1) (2023)
Katie R Flaherty, Stephanie Kucykowicz, Johannes Schroth, Will Traves, Kyle T Mincham, George E Finney
Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key? Immunotherapy advances 3 (1) (2023)
Shuya Kaneko, Fumiaki Sakura, Kay Tanita, Asami Shimbo, Ryusuke Nambu, Masashi Yoshida, Shuichiro Umetsu, Ayano Inui, Chizuru Okada, Miyuki Tsumura, Mamiko Yamada, Hisato Suzuki, Kenjiro Kosaki, Osamu Ohara, Masaki Shimizu, Tomohiro Morio, Satoshi Okada, Hirokazu Kanegane
Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function. Immunotherapy advances 3 (1) (2023)
María José Mansilla, Catharien M U Hilkens, Eva M Martínez-Cáceres
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy advances 3 (1) (2023)
Lars Klareskog, Lars Alfredsson
Prevention vs treatment of rheumatoid arthritis. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Patrícia Silva Santos Ribeiro, Hanneke L D M Willemen, Sabine Versteeg, Christian Martin Gil, Niels Eijkelkamp
NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain. Immunotherapy advances 3 (1) (2023)
Natalie Mona Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen M Ross, Frank Heuts, Yassin Elfaki, Luke P Houghton, Toby Talbot, Amna Sheri, Alexandra Pender, David Chao, Lucy Sarah Kate Walker
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy advances 3 (1) (2023)
Ester Gea-Mallorqui, Sarah Rowland-Jones
DC-targeting lentivectors for cancer immunotherapy. Immunotherapy advances 3 (1) (2023)
Natalie Mona Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen M Ross, Frank Heuts, Yassin Elfaki, Luke P Houghton, Toby Talbot, Amna Sheri, Alexandra Pender, David Chao, Lucy Sarah Kate Walker
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
Time to treat the climate and nature crisis as one indivisible global health emergency. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Sandra Kleinau
Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma. Immunotherapy advances 3 (1) (2023)
Melissa M Christodoulidou, Neil A Mabbott
Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Winston M Zhu, Mark R Middleton
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunotherapy advances 3 (1) (2023)
Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw, null null
Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunotherapy advances 3 (1) (2023)